HITECHAnswers has published another worthwhile read for those of us who like to think big picture. It's First Glimpse at Stage 3 Meaningful Use Measures by Mary Mosquera, Senior Editor, Government Health IT.
I'm intentionally keeping my comments short today in the hope you'll click the link and read what Ms. Mosquera has to say. If you've been following the long-term trends, you already knew that clinical decision support would be the crown jewel of Stage 3 certification. No surprise, the Health IT Policy Committee confirmed that direction at its August 1 meeting.
To date however, most talk of CDS centers around drugs: drug-drug interactions; drug allergy alerts, and so on. And, in this area, an authoritative resource is sought, versus every vendor coming up with its own rules. Great concept! That might leave vendors a place still to set themselves apart - for example, helping with the everyday decisions made by providers that are not medication related yet lead to better patient outcomes.
In the meantime, read Mary Mosquera and maybe a related post or two. Enjoy!
Alistair Jackson, M.Ed.
No comments:
Post a Comment